Precision Medicine Trailblazer Nuvectis Pharma Secures FDA Orphan Drug Designation for NXP800
The Orphan Drug Designation is more than just a regulatory milestone—it’s a strategic advantage that could dramatically reshape the future of Nuvectis Pharma.
Statement From FDA Commissioner Robert M. Califf, M.D., on Ensuring Access to Safe and Effective Treatments
Joint Statement with CMS Administrator Chiquita Brooks-LaSure
FDA Issues Improvement Plan Focused on Modernizing Foodborne Illness Outbreak Responses
The following is attributed to Frank Yiannas, FDA Deputy Commissioner for Food Policy and Response, and Stic Harris, D.V.M. director of the FDA's Coordinated Outbreak Response and Evaluation Network
FDA Approves First Treatment for Common Type of Post-Transplant Infection That Is Resistant to Other Drugs
Approval is for cytomegalovirus, a type of herpes virus
FDA Approves Besremi to Treat Adults With Polycythemia Vera
The FDA granted the approval of Besremi to PharmaEssentia Corporation
